AstraZeneca approached Gilead about potential merger - Bloomberg News

  • 📰 Reuters
  • ⏱ Reading Time:
  • 2 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 4%
  • Publisher: 97%

대한민국 뉴스 뉴스

대한민국 최근 뉴스,대한민국 헤드 라인

AstraZeneca Plc has approached rival drugmaker Gilead Sciences Inc about a potential merger, Bloomberg News reported on Sunday, citing people familiar with the matter.

FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease , during the outbreak of the coronavirus disease , in Oceanside, California, U.S., April 29, 2020.

Mike Blake/File Photo

 

귀하의 의견에 감사드립니다. 귀하의 의견은 검토 후 게시됩니다.

Under His eye...

Of course they did. THE ONLY ONES GETTING RICHER WHILE THE POOR BECOMES MORE IMPOVERISHED....

That's an interesting news, but it may be too early

Hope combined R&D could expedite coronavirus vaccine.

이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오:

 /  🏆 2. in KR

대한민국 최근 뉴스, 대한민국 헤드 라인

Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.

2 billion doses of Oxford COVID-19 vaccine planned after Gates funding - Business InsiderBusiness Insider is a fast-growing business site with deep financial, media, tech, and other industry verticals. Launched in 2007, the site is now the largest business news site on the web. It is a goodwill initiative, but a mistake. In fact, it may lead to finding vaccine later than expected! How? Well big pharma will push away alternatives that may work but they are not working on. Big money close to power always lead to corruption. I just hope that I am wrong. __MJDr It remains unclear whether the vaccine will work 🤨 So actual cost is $2.50/dose ($750M/300Mdoses). What will be the sale price then?
출처: BusinessInsider - 🏆 729. / 51 더 많은 것을 읽으십시오 »